DAWN - Company ID 0001845337
The table below shows Day One Biopharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$103.76M | -$78.11M | -$146.85M | -$109.87M | -$48.54M | -$13.49M |
| Capital expenditure | $320.00K | $2.17M | $224.00K | $26.00K | $0.00 | $92.00K |
| Investing cash flow | $174.65M | -$230.99M | $128.38M | -$255.07M | -$8.00M | -$92.00K |
| Dividends paid | - | - | - | - |
Day One Biopharmaceuticals, Inc. reported operating cash flow of -$103.76M for fiscal year 2025. That is down 32.8% from -$78.11M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$4.51M (FY 2019) to -$103.76M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.22M | $203.29M | $164.00M | $165.90M | $297.12M | $29.98M |